SEC	Form	4
-----	------	---

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

affirmative defense conditions of Rule

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
(City)	(State)	(Zip)						
BEDMINSTER	NJ	07921	_					
(Street)			_	Form filed by More than One Reporting Person				
1545 ROUTE 206 SOUTH SUITE 302		1E 302		X Form filed by One Reporting Person				
C/O MATINAS BIOPHARMA HOLDINGS, INC.		· · · · · · · · · · · · · · · · · · ·	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Last)	(First)	(Middle)	11/01/2025	below) below)				
			 3. Date of Earliest Transaction (Month/Day/Year) 11/01/2023 	Officer (give title Other (specify				
<u>CONRAD HERBERT J</u>				X Director 10% Owner				
1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol <u>Matinas BioPharma Holdings, Inc.</u> [MTNB]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
TUDS-T(C). See Inst								

1. Title of Security (Instr. 3) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 6. Ownership 7. Nature of 2. Transaction 2A. Deemed 3. 5. Amount of Date Execution Date, Transaction Securities Form: Direct (D) Indirect Beneficially Owned (Month/Dav/Year) if anv Code (Instr. or Indirect (I) Beneficial 8) Following Reported (Month/Day/Year) (Instr. 4) Ownership Transaction(s) (Instr. 4) (A) or (D) (Instr. 3 and 4) Code v Amount Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transac Code (In 8)				Expiration Date (Month/Day/Year) A) or of (D)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	Owned	Ownership Form:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock option (right to buy)	\$0.2088	11/01/2023	A		437,244		(1)	11/01/2033	Common Stock	437,244	\$0	437,244	D	

Explanation of Responses:

1. The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

/s/ Keith A. Kucinski, attorney-in fact for Herbert J. Conrad

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940